Latest Education News

4DMedical secures a major commercial breakthrough with Stanford University adopting its FDA-cleared CT, VQ™ technology, while its partnership with AstraZeneca rapidly scales lung screening across Brazil.

TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.

EDU Holdings reports a 26% rise in new student enrolments for Term 4, 2025 compared to the prior term, signaling resilience amid sector softness and recent regulatory changes.

Raiz Invest Limited has reported record first-quarter FY26 results, hitting $2 billion in funds under management and expanding its customer base to over 335,000. The fintech firm also raised its earnings guidance, underpinned by new product launches and strategic partnerships.

Qoria Limited reported a strong start to FY2026, with annual recurring revenue climbing 25% year-on-year and record cash receipts of $46.3 million, prompting an upgrade to its full-year revenue guidance.

Raiz Invest has hit a record $2 billion in funds under management, driven by strong customer growth and innovative product launches. The fintech’s latest quarter also saw strategic partnerships expand its market reach.

Janison Education Group has won a five-year, $1.4 million contract with the Western Australian School Curriculum and Standards Authority to deliver its Online Literacy and Numeracy Assessment, marking a strategic expansion beyond New South Wales.

Qualitas Real Estate Income Fund (QRI) has announced a $162 million non-renounceable entitlement offer at $1.60 per unit, aiming to capitalize on a robust pipeline of commercial real estate loans. The offer provides existing investors an opportunity to deepen exposure to Australia's evolving private credit market.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Immuron Limited reports a robust 34% year-on-year sales increase for Q1 FY26, driven by strong growth in Australia and the USA, while Canadian sales dip seasonally. The company’s marketing efforts and expanding retail presence underpin this momentum.

Fiducian Group Limited has reported a robust 23% increase in net profit after tax for the year ended June 2025, driven by strong inflows and resilient performance across its financial planning, platform administration, and investment management segments despite challenging market conditions.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.